Treatment of head and neck cancer [6]

New England Journal of Medicine

Volumn 358, Issue 10, 2008, Pages 1076-1077

  Nutting, Christopher M ^a   Bhide, Shreerang A ^b   Harrington, Kevin J ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HEAD AND NECK CANCER; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; NOTE; SURVIVAL; MORTALITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; SURVIVAL ANALYSIS; CARBOPLATIN; CISPLATIN; FLUOROURACIL; SURVIVAL RATE; TAXOIDS;

EID: 40449135071     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc073274     Document Type: Letter

References (2)